2019
Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer
Caram M, Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Network Open 2019, 2: e192589. PMID: 31002323, PMCID: PMC6481456, DOI: 10.1001/jamanetworkopen.2019.2589.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalHealthcare DisparitiesHumansMalePractice Patterns, Physicians'Prostatic NeoplasmsRetrospective StudiesTissue ExtractsUnited StatesConceptsMinimally symptomatic metastatic castration-resistant prostate cancerSipuleucel-TProstate cancerSymptomatic metastatic castration-resistant prostate cancerDatabase of commercially insured patientsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAge of patientsRetrospective cohort studyFactors associated with useAssociated with patientsCommercially insured patientsPatterns of treatmentConcurrent therapyTreated patientsCohort studyMultivariate analysisCancer therapyTherapyPatientsPhysician factorsCancerBarriers to treatmentBinomial logistic regressionLogistic regression
2018
Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram M, Estes J, Griggs J, Lin P, Mukherjee B. Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer 2018, 18: 258. PMID: 29510667, PMCID: PMC5840834, DOI: 10.1186/s12885-018-4166-3.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerFirst-line therapyProstate cancerSystemic treatmentFirst-lineSystemic treatment of advanced prostate cancerTreatment of metastatic castration-resistant prostate cancerTreatment of advanced prostate cancerResultsOur final analysisAdvanced prostate cancerFirst line therapyFood and Drug AdministrationNational insurance providerLine therapySequence of treatmentTreatment patternsDisease courseStudy cohortPrescription ratesPrescribed drugsDrug AdministrationIncreased survivalCancerTherapy
2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce density